Wall Street analysts forecast that Idexx Laboratories (IDXX) will report quarterly earnings of $2.12 per share in its upcoming release, pointing to a year-over-year increase of 3.4%. It is anticipated that revenues will amount to $890.61 million, exhibiting an increase of 7.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have r ...

IDEXX Laboratories, Inc. (IDXX) is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. A key element of IDEXX’s customer engagement strategy is the expansion of its commercial footprint in a disciplined approach. Robust demand for the company’s cloud-based offerings buoys optimism.However, negative solvency and foreign exchange fluctuations are discouraging for the company’s operations.In the past year, this Zacks Rank #3 (Hold) stock h ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Idexx Laboratories (IDXX) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This Animal diagnostic and health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 8.3 ...

IDEXX Laboratories, Inc. (IDXX) is set to release fourth-quarter 2023 results on Feb 5 before the opening bell.The company posted adjusted earnings per share (EPS) of $2.53 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 6.8%. IDEXX Laboratories beat earnings estimates in all the trailing four quarters, the average surprise being 7.64%.Let’s look at how things have shaped up before this announcement.Factors at PlayIDEXX’s Companion Animal Group (“CAG”) Diagnostics recurring rev ...

IDEXX Laboratories, Inc. (IDXX) recently expanded its Fecal Dx antigen testing platform with the addition of Cystoisospora —  a common intestinal parasite that is the source of diarrhea, weight loss and dehydration — primarily in young dogs and cats. Fecal Dx antigen testing with Cystoisospora will be offered at IDEXX Reference Laboratories in March in North America and globally in third-quarter 2024.The recent development will bolster IDEXX’s Livestock, Poultry and Dairy (LPD) business.More on Fecal Antige ...

Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infectionsWESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX's Fecal Dx antigen testing offers earlie ...

AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology casesThe global launch of the IDEXX inVue Dx analyzer will begin in late 2024WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind slide-free cellular analyzer to detect the most common cytologic changes ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Dela ...

Financial Data and Key Metrics Changes - IDEXX achieved a 10% organic revenue growth in Q2 2023, with CAG diagnostic recurring revenues increasing by 12% [58][71] - Operating expenses decreased by 17% year-on-year, contributing to a 71% increase in EPS to $2.67 per share [6][58] - Gross profit increased by 11% in Q2, with gross margins at 60.7%, up 160 basis points on a comparable basis [62][71] Business Line Data and Key Metrics Changes - Veterinary software and diagnostic imaging revenues grew by 13% organically, supported by high levels of recurring software growth [106] - CAG instrument revenues were down 6% organically, influenced by high-priority comparisons and program pricing effects [3] - Water revenue increased by 9% organically, benefiting from net price improvements and the integration of the TectaPDS acquisition [5] Market Data and Key Metrics Changes - U.S. revenues exceeded $1 billion in the first half of 2023, reflecting strong execution across all regions [9] - CAG diagnostic recurring revenue growth in the U.S. was 12%, while international growth was 10% [59][60] - IDEXX experienced strong growth in premium instrument placements, with a 15% increase globally [67][74] Company Strategy and Development Direction - The company is focused on enhancing diagnostic solutions and expanding its commercial reach to drive long-term growth [67][68] - IDEXX plans to maintain its operational outlook for Q3, expecting organic revenue growth at the lower end of its full-year guidance range [8][108] - The company is strategically expanding its U.S. customer-facing organization to capitalize on attractive opportunities [112] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about long-term growth prospects in the U.S. and internationally, despite near-term macroeconomic challenges [19][20] - The company anticipates a normalization of clinical visit trends in the second half of 2023, supported by strong underlying demand [117][118] - Management highlighted the importance of maintaining high customer retention levels and increasing diagnostic frequency [73][118] Other Important Information - IDEXX will host its annual Investor Day on August 10, 2023, to provide updates on strategy and growth potential [13] - The company expects foreign exchange impacts to reduce EPS by approximately $0.21 per share for the full year [109] Q&A Session Summary Question: Trends in clinical visits in the U.S. - Management noted that clinical visit trends were consistent throughout Q2, with expectations for improvement in the second half of 2023 [117][118] Question: Competitive dynamics between corporate and independent practices - Management indicated that both types of practices are increasingly interested in IDEXX's solutions, with corporate practices focusing on growth and standardization [16] Question: Impact of weather on international markets - Management acknowledged that extreme weather events could affect pet owner behavior and clinic visits, particularly in Europe [32] Question: Pricing strategy for 2024 - Management reiterated a consistent outlook for net price improvement in the second half of 2023 but did not provide specific plans for 2024 [90][121] Question: Differences in clinical visit growth between corporate and independent clinics - Management observed similar growth profiles for both types of clinics, with a focus on preventive care driving engagement [92][125]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...